Theravance Biopharma, Inc. Contract Liability (Deferred Revenue)
Theravance Biopharma, Inc. (TBPH) had Contract Liability (Deferred Revenue) of $24.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-11-09
- 2023-09-30: Contract with Customer, Liability, Current $24.00K.
- 2023-06-30: Contract with Customer, Liability, Current $24.00K.
- 2023-03-31: Contract with Customer, Liability, Current $24.00K.
- 2022-12-31: Contract with Customer, Liability, Current $24.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-09-30 | $24.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $24.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $24.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $24.00K 10-Q · filed 2023-11-09 |
| 2022-09-30 | $24.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $24.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $98.00K 10-Q · filed 2022-05-06 |
| 2021-12-31 | $98.00K 10-K · filed 2023-03-01 |
| 2021-09-30 | $2.90M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $5.69M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $7.66M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $11.52M 10-K · filed 2022-02-28 |
| 2020-09-30 | $18.20M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $25.06M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $23.19M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $31.57M 10-K · filed 2021-02-26 |
| 2019-09-30 | $33.75M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $43.31M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $42.52M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $43.40M 10-K · filed 2020-02-27 |
| 2018-09-30 | $57.24M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $54.48M 10-Q · filed 2018-08-02 |
| 2017-12-31 | $125.00K 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |